title: Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release.
abstract: The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double-blind trial. Patients with newly diagnosed mild-to-moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide-PR (n = 219) or torasemide-IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide-PR group (11.6 +/- 7.1 mmHg, 95% confidence interval [CI] 10.6-12.5) versus torasemide-IR (11.3 +/- 7.5 mmHg, 95% CI 10.2-12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide-PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24-h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide-PR group (128.4 +/- 9.9 mmHg vs. 133.5 +/- 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar.
authors.affiliation: Unit of Hypertension, Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. aroca@hsp.santpau.es
authors.forename: Alex
authors.initials: A
authors.lastname: Roca-Cusachs
authors.forename: Joaquín
authors.initials: J
authors.lastname: Aracil-Vilar
authors.forename: Carlos
authors.initials: C
authors.lastname: Calvo-Gómez
authors.forename: José-Vicente
authors.initials: JV
authors.lastname: Vaquer-Pérez
authors.forename: Félix
authors.initials: F
authors.lastname: Laporta-Crespo
authors.forename: María-José
authors.initials: MJ
authors.lastname: Rojas-Serrano
authors.forename: Antonio
authors.initials: A
authors.lastname: Guglietta
authors.forename: Savion
authors.initials: S
authors.lastname: Gropper
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D003692:Delayed-Action Preparations; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013030:Spain; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D000077786:Torsemide; D016896:Treatment Outcome; D014554:Urination / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004232:Diuretics; D013449:Sulfonamides; D000077786:Torsemide